VC-backed Orchard Therapeutics raises $150m series-C

A number of new backers took part in the round, namely RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Sphera Global Healthcare, Medison Venture Partner, Driehaus Capital Management and Ghost Tree Capital Group. Existing investors include Temasek, Baillie Gifford, RTW Investments, Cowen Healthcare Investments and Agent Capital.

Orchard is investing in the registration and launch of its three most advanced treatments for adenosine deaminase severe combined immunodeficiency, metachromatic leukodystrophy and Wiskott–Aldrich syndrome.

Previous funding
F-Prime led a £21m series-A for Orchard in May 2016, and later in the year the company received a $20m grant from the California Institute of Regenerative Medicine.

Baillie Gifford and ORI Capital then co-led an £85m series-B funding round for Orchard in December 2017. F-Prime and ORI also took part in the round, alongside new backers Temasek, Cowen Healthcare Investments, Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4Bio Capital.

Company
Dual-headquartered in London and California, Orchard is a clinical-stage biotechnology company that develops gene therapies for rare disorders. The company works in partnership with gene-therapy centres including University College London, Great Ormond Street Hospital, the University of Manchester, Central Manchester University Hospital, the University of California and Boston Children's Hospital.

People
Orchard Therapeutics – Mark Rothera (president, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture